Compare EPAC & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPAC | PHVS |
|---|---|---|
| Founded | 1910 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | N/A | 2021 |
| Metric | EPAC | PHVS |
|---|---|---|
| Price | $39.53 | $27.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $50.50 | $39.44 |
| AVG Volume (30 Days) | ★ 422.9K | 205.4K |
| Earning Date | 12-17-2025 | 11-12-2025 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | ★ 0.98 | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $615,911,000.00 | N/A |
| Revenue This Year | $5.17 | N/A |
| Revenue Next Year | $5.97 | N/A |
| P/E Ratio | $24.01 | ★ N/A |
| Revenue Growth | ★ 3.91 | N/A |
| 52 Week Low | $35.01 | $11.51 |
| 52 Week High | $47.47 | $29.80 |
| Indicator | EPAC | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 47.06 | 59.02 |
| Support Level | $40.00 | $26.73 |
| Resistance Level | $42.43 | $28.20 |
| Average True Range (ATR) | 0.93 | 1.32 |
| MACD | -0.13 | 0.17 |
| Stochastic Oscillator | 14.63 | 82.37 |
Enerpac Tool Group Corp provides high-precision hydraulic and mechanical tools, controlled-force products, and heavy lifting solutions. Operating mainly through its Industrial Tools & Services (IT&S) segment, the company designs, manufactures, and distributes branded tools, and offers maintenance, bolting, machining, joint integrity, and equipment rental services across industries such as oil & gas, manufacturing, power generation, and infrastructure. Its key products include hydraulic cylinders, pumps, torque wrenches, and bolt tensioners under the brands ENERPAC and HYDRATIGHT. The company serves customers internationally, with operations in the USA, Australia, Brazil, Germany, Saudi Arabia, the United Kingdom, and other countries, deriving the majority of its revenue from the USA.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.